Gut Microbiota, Immunity, and Disease: A Complex Relationship by Kosiewicz, Michele M. et al.
REVIEW ARTICLE
published: 05 September 2011
doi: 10.3389/fmicb.2011.00180
Gut microbiota, immunity, and disease: a complex
relationship
Michele M. Kosiewicz,Arin L. Zirnheld and PascaleAlard*
Department of Microbiology and Immunology, Health Sciences Center, University of Louisville, Louisville, KY, USA
Edited by:
Alain Stintzi, Ottawa Institute of
Systems Biology, Canada
Reviewed by:
DeborahThreadgill, North Carolina
State University, USA
Peter J.Turnbaugh, Harvard
University, USA
*Correspondence:
Pascale Alard, Department of
Microbiology and Immunology,
University of Louisville, 319 Abraham
Flexner way, Louisville, KY 40202,
USA.
e-mail: p0alar01@louisville.edu
Our immune system has evolved to recognize and eradicate pathogenic microbes. How-
ever, we have a symbiotic relationship with multiple species of bacteria that occupy the
gut and comprise the natural commensal ﬂora or microbiota. The microbiota is critically
important for the breakdown of nutrients, and also assists in preventing colonization by
potentially pathogenic bacteria. In addition, the gut commensal bacteria appear to be criti-
cal for the development of an optimally functioning immune system. Various studies have
shown that individual species of the microbiota can induce very different types of immune
cells(e.g.,Th17cells,Foxp3+ regulatoryTcells)andresponses,suggestingthatthecompo-
sitionofthemicrobiotacanhaveanimportantinﬂuenceontheimmuneresponse.Although
the microbiota resides in the gut, it appears to have a signiﬁcant impact on the systemic
immune response. Indeed, speciﬁc gut commensal bacteria have been shown to affect
disease development in organs other than the gut, and depending on the species, have
been found to have a wide range of effects on diseases from induction and exacerbation
to inhibition and protection. In this review, we will focus on the role that the gut microbiota
plays in the development and progression of inﬂammatory/autoimmune disease, and we
will also touch upon its role in allergy and cancer.
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INTERACTION BETWEEN THE GUT MICROBIOTA AND THE
IMMUNE SYSTEM
The trillions of commensal microorganisms that constitute the
intestinal microbiota are primarily composed of ﬁve bacterial
phyla,Firmicutes,Bacteroidetes,Actinobacteria,Proteobacteria,and
Fusobacteria. Bacteroidetes and Firmicutes predominate and rep-
resent ∼90% of the total gut microbiota (i.e.,25 and 65%,respec-
tively; Rajilic-Stojanovic et al., 2007). However, these proportions
can vary greatly between individuals and even within single indi-
vidual over time. Although commensal bacteria inhabit the entire
gut,greater numbers reside in the distal part of the small intestine
and in the large intestine or colon. Acquisition of the intesti-
nal microbiota occurs in the ﬁrst year of life and is inﬂuenced
by the maternal bacteria obtained during vaginal delivery (Ben-
net and Nord, 1987; Mandar and Mikelsaar, 1996; Penders et al.,
2006),versusCesareansection(Dominguez-Belloetal.,2010),and
breastfeeding (Yoshioka et al., 1983; Balmer and Wharton, 1989;
Harmsen et al.,2000; Hopkins et al.,2005). Early in life the major
shifts in the gut microbiota can be caused by antibiotics, dietary
changes,etc.(Koenigetal.,2011)asopposedtoapurelystochastic
model (Palmer et al.,2007). However,there is a lack of large-scale
studies of temporal variation in adults.
The gut microbiota plays a critical role in the breakdown
of indigestible complex plant polysaccharides, and provides
an important layer of defense against invasion by pathogenic
microorganisms. It is also required for proper development of the
immune system,as indicated by the fact that germ-free (GF) mice
have poorly developed lymphoid tissues. GF mice have spleens
with few germinal centers and poorly formed T and B cell zones,
hypoplastic Peyer’s patches, lower numbers of lamina propria
CD4+cellsandIgA-producingplasmacells(MacphersonandHar-
ris, 2004), and aberrant development and maturation of isolated
lymphoid follicles (Bouskra et al., 2008). The lymphoid organs of
GFmiceexhibitaberrantdevelopmentof TandBcellsubsets,and
more speciﬁcally, contain CD4+ T cells that are skewed toward
an T helper 2 (Th2) phenotype and produce little, if any, IFNγ
(Mazmanian et al., 2005), and have fewer and smaller germinal
centers (Bauer et al., 1963). There is also evidence that the micro-
biotaplaysakeyroleintheinductionof IgA(Klaasenetal.,1993b;
Talham et al., 1999) and maintenance of homeostasis of various
T cell populations in the gut, including regulatory T cells (Tregs),
and T helper 1 (Th1) and 17 (Th17) cells (Gaboriau-Routhiau
et al.,2009).
The commensal bacteria that reside in the gut are diverse, and
individual species appear, in some cases, to have distinct and
opposing roles. Some commensal bacteria appear to drive Treg
development preferentially, while others promote Th17 develop-
ment. In a comparative analysis of terminal ileal tissue from mice
maintained in conventional (CV) versus GF housing, tissue from
CV mice exhibited 5- to 10-fold higher IL-10 and Foxp3 mRNA
expression compared to GF mice, suggesting that the microbiota
can drive Foxp3+Treg induction and/or expansion in the intes-
tine (Gaboriau-Routhiau et al.,2009). Furthermore,in the Peyer’s
patchesandmesentericlymphnodes(LN)of naiveGFmice,Tregs
were at a decreased frequency, were less effective at suppressing
responder cell proliferation in vitro, and produced lower levels of
IL-10 and TGFβ than naive mice housed under speciﬁc pathogen-
free (SPF) conditions (Ishikawa et al., 2008). The colonization of
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GF mice with Bacteroides fragilis increases the suppressive capac-
ity of Tregs and induces anti-inﬂammatory cytokine production
by Foxp3+ T cells in the gut (Mazmanian et al., 2008). Similarly,
colonization of GF mice with a cocktail of Clostridium strains
increased dramatically the frequency of IL-10-producing Helios−
Tregs (induced Tregs) in the colonic lamina propria (Atarashi
et al., 2011). Numerous studies have also found that Tregs are
induced following gavage with gut commensal bacteria of either
the Lactobacillus or Biﬁdobacterium genus (Di Giacinto et al.,
2005; O’Mahony et al., 2008; Karimi et al., 2009; Livingston et al.,
2010; Zhang et al., 2010). In contrast, Th17 cell responses appear
to be induced by a restricted number of microbial species, e.g.,
segmented ﬁlamentous bacteria (SFB). Candidatus arthromitus,
commonly called SFB, are Gram-positive bacteria of the Firmi-
cutes phylum and most closely related to the Clostridium genus
(Snel et al., 1995). These bacteria colonize the small intestine
and have been shown to stimulate the production of secretory
IgA (Klaasen et al., 1993b; Talham et al., 1999) and to activate
CD8αβ+TCRαβ+ intraepithelialcellsinthesmallintestine(Ume-
saki et al., 1995). The SFB are thought to play a key role in the
maturation of the adaptive mucosal immune response in the gut.
Indeed, SFB colonization of GF mice has been shown to induce
differentiation of primarily IL-17+ T cells (Ivanov et al., 2008,
2009; Gaboriau-Routhiau et al., 2009) and to a far lesser extent,
IFNγ+Th1andIL-10+Treg cells (Gaboriau-Routhiauetal.,2009).
These data indicate that SFB can promote the development of
intestinalTh17cells,apopulationof Tcellsthatisnotonlyimpor-
tant for ﬁghting bacterial infection, but is also involved in the
pathogenesis of a number of inﬂammatory and autoimmune dis-
eases. A microbiota favoring SFB could,therefore,have an impact
on the immune response, and consequently, on the development
of Th17-mediated inﬂammatory/autoimmune diseases in the gut
and at distant sites in predisposed individuals. The speciﬁc mech-
anismsthatleadtothepreferentialinductionof TregsversusTh17
cellsbyvariouscommensalbacteriaarecurrentlyunknown.How-
ever, DNA derived from commensal bacteria has been shown
to play a major role in intestinal homeostasis through toll-like
receptor9(TLR9)engagement,andappearstobeinvolvedincon-
trollingthebalancebetweenTregsandeffectorcells.Indeed,TLR9
deﬁcient (TLR9−/−) mice exhibit increases in intestinal Foxp3+
Tregs, and decreases in IL-17 and IFN-γ production by compar-
ison to wild-type mice (Hall et al., 2008). One could speculate
that speciﬁc commensal species may differentially modulate the T
effector/Treg cell balance via this mechanism, since the ability of
gut commensal bacteria to stimulate TLR9 varies and depends on
the frequency of CG dinucleotides (Dalpke et al., 2006).
The composition of the microbiota can be inﬂuenced by vari-
ous factors,including diet and exposure to antibiotics.Analysis of
the fecal microbiota of humans and 59 other mammalian species
has shown that the gut microbiota of humans living a mod-
ern lifestyle is typical of omnivorous primates (Ley et al., 2008).
Moreover, feeding GF mice colonized with human fecal micro-
bial communities a high-fat, high sugar “Western” diet instead
of a low-fat, plant polysaccharide-rich diet signiﬁcantly altered
the microbiota composition,resulting in an increase in Firmicutes
and decrease in Bacteroidetes (Turnbaugh et al., 2009). In con-
trast, a diet very high in ﬁber has been associated with increases
in Bacteroidetes and a much lower abundance of Firmicutes in
humans (De Filippo et al., 2010), although other factors may
confoundthesecomparisons.Interestingly,ﬂuctuationsinthepro-
portions of these types of commensal bacteria have been found
in patients and animals with inﬂammatory/autoimmune diseases
(see below). In addition, antibiotic treatment is usually followed
by a decrease in the diversity of the microbiota. Although the
composition of the microbiota is similar in the days or weeks
following the termination of treatment, some bacterial members
are lost from the community indeﬁnitely (Jernberg et al., 2007;
Jakobsson et al.,2010). Furthermore,different types of antibiotics
differentiallyaffectbacteriaand,consequently,immunecelldevel-
opment. Antibiotic treatment (ampicillin, gentamicin, metron-
idazole, neomycin, and vancomycin) that reduced bacteria from
theFirmicutes phylum while increasing the proportion of bacteria
from the Bacteroidetes, phylum was associated with a reduction
in mucosal CD4+T cells expressing IFNγ and IL-17 (Hill et al.,
2010). Similarly, vancomycin or ampicillin treatment, both of
which inhibit Gram-positive bacteria, dramatically decreased the
numbers of Th17 cells in the lamina propria. In contrast,metron-
idazole or neomycin, which target anaerobes and Gram-negative
bacteria,hadlittleeffectontheTh17cellpopulation(Ivanovetal.,
2008). Because the microbiota profoundly affects immune system
development and maturation, it is not surprising that modula-
tion of the balance between the various commensal bacteria can
inﬂuenceinﬂammatory/autoimmunediseasedevelopmentand/or
progression.
INVOLVEMENT OF COMMENSAL BACTERIA IN PROTECTION
AGAINST AUTOIMMUNITY
The less than 100% concordance rate for autoimmune diseases
in monozygotic twins (e.g., <40% for type 1 diabetes; Hyttinen
et al.,2003),suggests that environmental factors can have a strong
inﬂuence on inﬂammatory/autoimmune disease development.
The composition of the microbial community that comprises
the microbiota varies between individuals including monozygotic
twins. Because the gut commensal bacteria inﬂuences the devel-
opment of the immune system, the microbiota could be one of
the environmental factors that affects inﬂammatory/autoimmune
diseasedevelopmentingeneticallysusceptibleindividuals,i.e.,dif-
ferences in its composition could contribute to the lower than
expected concordance rate in monozygotic twins. The composi-
tion of the gut microbiota may,therefore,either confer protection
or trigger disease in genetically susceptible individuals.
Considerable evidence indicates that the composition of the
microbiotacaninﬂuencethedevelopmentof intestinalinﬂamma-
tion. Some commensal bacteria may induce intestinal inﬂamma-
tionwhileotherscontrolit.Thecommensalscapableofcontrolling
inﬂammation in the gut mediate their effect either by balanc-
ing the immune response in favor of regulation or by controlling
bacteria that may directly mediate intestinal inﬂammation. With
regard to balancing the immune response, commensal bacteria
from the Bacteroidetes and Firmicutes phyla appear to induce
Tregs that can control Th17 cells that are responsible for intesti-
nal inﬂammation. In a recent report, colonization of GF mice
with the human commensal, B. fragilis, was shown to induce IL-
10 production and Foxp3 expression, decrease Th17 cells and
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prevent colitis development. Furthermore, injection of polysac-
charideA (PSA) isolated from B. fragilis was found to recapitulate
the effects of colonization with B. fragilis (Mazmanian et al.,
2008; Round and Mazmanian,2009),with PSA-induced signaling
through TLR2 expressed by Tregs promoting tolerance (Round
et al., 2011). In addition, mice orally inoculated with murine
Clostridium species belonging to clusters IV and XIVa (Firmicutes
phylum) were resistant to colitis development and exhibited an
increase in the frequency of colonic Tregs (Atarashi et al., 2011).
Various human Lactobacillus strains (of the Firmicutes phylum)
have also been shown to be protective in several animal mod-
els of colitis, including the TNBS-induced and IL-10 deﬁcient
mouse models of colitis, and were found to mediate their effect
via induction of Tregs (Di Giacinto et al., 2005; O’Mahony et al.,
2008; Livingston et al., 2010). Commensal bacteria can also affect
other potentially pathogenic bacteria; for example, commensal
bacteria from the Actinobacteria phylum appear to control the
levels of other commensal bacteria that cause intestinal inﬂam-
mation. Administration of Biﬁdobacterium animalis subsp. Lactis
(Actinobacteria phylum) reduced intestinal inﬂammation in the
T-bet−/−Rag2−/− modelof colitis.Thiswasassociatedwithacon-
comitant reduction in Enterobacteriaceae levels, the commensal
bacteria shown to initiate intestinal inﬂammation in this colitis
model. Moreover, the authors reported that the fecal levels of
Biﬁdobacterium in untreated T-bet−/−Rag2−/− m i c ew e r el o w e r
compared to control mice, and found that the Biﬁdobacterium
fecal levels were inversely related to the colitis score (Veiga
et al., 2010). Taken together, these studies demonstrate that sev-
eral different species of commensal bacteria can control inﬂam-
mation in the gut via different mechanisms, e.g., by directly
regulating the immune response or by affecting the composi-
tion of the microbiota and reducing other disease-mediating
commensals.
Commensalbacteriacanalsohaveaprotectiveeffectatsitesdis-
tant from the gut. The results of one recent study suggest that the
microbiotaplaysanimportantroleintype1diabetesingenetically
susceptiblemice.Type1diabetes-susceptibleNODmicethatwere
crossedwithMyD88−/− mice(NODMyD88−/−)werefoundtobe
protectedfromtype1diabetes.Thisprotectionappearedtoinvolve
changesinthecompositionofthemicrobiota,sinceprotectionwas
abrogated when NODMyD88−/− mice were treated with antibi-
otics or derived and maintained under GF conditions. A com-
parisonof thegutmicrobiotabetweenNODMyD88sufﬁcientand
NODMyD88−/− miceconﬁrmedthatthereweredifferencesinthe
microbiotacompositionwhichcouldaccountforthedifferencesin
disease susceptibility. The NODMyD88−/− m i c eh a dal o w e rFir-
micutes/Bacteroidetes ratio than the NODMyD88 sufﬁcient mice,
and an enrichment in cecal Lactobacillacae, Rikenellaceae, and
Porphyromonadaceae.Finally,wild-typeNODmicethatwerecolo-
nized at birth with microbiota from NODMyD88−/− mice exhib-
ited signiﬁcantly reduced islet inﬁltration compared to untreated
NOD mice (Wen et al., 2008), i.e., the microbiota from the
NODMyD88−/− miceconferredsomeprotectionfromdiabetesto
wild-typeNODmice.Moreover,arecentpublicationhasreported
that female NOD mice colonized with SFB exhibited a large Th17
population in the lamina propria of the small intestine and were
protected from developing type 1 diabetes (Kriegel et al., 2011).
These ﬁndings corroborate studies showing that Th17 cells do not
directlymediatetype1diabetesinNODmice(Bendingetal.,2009;
Martin-Orozcoetal.,2009),andinfact,appeartoactasregulatory
cells that protect against disease development (Han et al., 2010;
Nikoopouretal.,2010).Interestingly,arecentstudyhasshownthat
Th17 cell pathogenicity can be controlled in the small intestine,
where pro-inﬂammatory Th17 cells can acquire a regulatory phe-
notype (rTh17) that includes in vivo immunosuppressive proper-
ties(Espluguesetal.,2011).Takentogether,thesedatasuggestthat
gutmicrobiotahasasigniﬁcant,ifcomplex,inﬂuenceonthedevel-
opmentofinﬂammatory/autoimmunediseases.Anotherstudyhas
found that the microbiota plays a protective role in a model of
collagen-induced arthritis. The study found that rats maintained
in a GF environment developed more severe rheumatoid arthritis
(RA) than rats maintained in a conventional environment, sug-
gestingthatthemicrobiotahadasuppressiveeffectonRAdevelop-
ment(Brebanetal.,1993).Lastly,aseriesof studieshasshownthat
the microbiota can protect against central nervous system (CNS)
disease. Oral administration of antibiotic, leading to a reduction
in bacteria from the Firmicutes phylum, but a relative increase in
bacteriafromtheBacteroidetes phylum,impairedthedevelopment
of myelin oligodendrocyte glycoprotein (MOG) or proteolipid
protein-induced experimental autoimmune encephalitis (EAE) in
mice.Inthisstudy,protectionwasassociatedwithdiminishedpro-
inﬂammatory responses, higher numbers of Tregs in mesenteric
LN and potent IL-10-producing Foxp3+ Tregs that were present
in the LN (Ochoa-Reparaz et al., 2009, 2010). Moreover, oral
administrationofPSAisolatedfromB.fragilis (oftheBacteroidetes
phylum) was able to prevent EAE development via enhancement
of CD103+ DC that converted naïve T cells into IL-10-producing
Foxp3+ Tregs, suggesting that antibiotic-mediated protection is
mediatedtheincreaseinBacteroidetes (Ochoa-Reparazetal.,2009,
2010).Finally,oraladministrationofprobiotics,includingtheLac-
tobacillus and Biﬁdobacterium species, has been shown to protect
againstdevelopmentof variousautoimmunediseasessuchastype
1 diabetes (Matsuzaki et al., 1997; Calcinaro et al., 2005), exper-
imental autoimmune encephalomyelitis (Lavasani et al., 2010),
experimental RA (Kato et al., 1998; Baharav et al., 2004; So et al.,
2008), and systemic lupus erythematosus (personal observation;
Alard et al., 2009), via induction of IL-10-producing Tregs and
attenuation of Th1 and Th17 cytokines. It is not clear whether
the Tregs are induced upon direct interaction with the probi-
otics and/or via stimulation with tolerogenic antigen presenting
cells that have been induced by the probiotics. We have, however,
shownrecentlythatdendriticcellsculturedwithLactobacillus casei
shift their cytokine proﬁle in favor of IL-10, and are able to pre-
vent type 1 diabetes development upon injection into NOD mice.
Sinceasingleinjectionof L.casei-treatedDCissufﬁcienttomedi-
ate long-term protection, the mechanism in this case most likely
involves induction of regulatory cells (Manirarora et al., 2011).
Altogether,thesedataemphasizetheimportanceof abalancedgut
microbiota that can induce a protective immune response capable
of suppressing inﬂammation in organs distant from the gut, via
inductionoftolerogenicDCandTregs.Howthesecellstrafﬁcfrom
the gut to the distal lymph nodes and possibly to the peripheral
tissue(CNS,joint,pancreas)iscurrentlyunknownandremainsto
be determined.
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Studies have indicated that the composition of the microbiota
can have a signiﬁcant effect on the development of inﬂamma-
tory/autoimmune disease in humans. The composition of the gut
microbiota differs greatly in subsets of patients with inﬂamma-
tory bowel disease (IBD),including Crohn’s disease and ulcerative
colitis, compared to non-IBD individuals. The microbiota of IBD
patients is characterized by depletion of Bacteroidetes and Firmi-
cutes (Frank et al., 2007). More speciﬁcally, recurrence of Crohn’s
disease was associated with decreases in the relative proportion of
Faecalibacteriumprausnitzii,abacteriumbelongingtoClostridium
cluster IV, in these patients (Sokol et al., 2009). In animal studies,
F. prausnitzii has been shown to have anti-inﬂammatory effects,
and oral administration of F. prausnitzii has been found to reduce
theseverityofTNBS-inducedcolitis(Sokoletal.,2008).Thesedata
suggest that restoration of the microbial balance in IBD patients
maybeagoodstrategytotreatthisdisease,andinfact,administra-
tion of VSL#3, a cocktail of several Lactobacillus species (L. Casei,
Lactobacillus plantarum, Lactobacillus acidophilus, and Lactobacil-
lus delbrueckii), Biﬁdobacterium species (Biﬁdobacterium longum,
Biﬁdobacteriumbreve,andBiﬁdobacteriuminfantis)andaStrepto-
coccussalivarius subsp.,Thermophilus,hasbeenshowntodecrease
ulcerativecolitisinpatientswithmildtomoderatelyactiveulcera-
tive colitis (Sood et al.,2009;Tursi et al.,2010). Studies in patients
with early RA have also found that Biﬁdobacteria and B. fragilis
in the gut are decreased (Vaahtovuo et al., 2008), suggesting that
alteration in the abundance of these two commensal species may
inﬂuencethepathogenesisof RA.However,inpatientswithestab-
lished disease,the possibility that an alteration in the composition
of the microbiota may be a consequence rather than a cause of the
disease cannot be ruled out.
In conclusion, commensal bacteria belonging to the Biﬁdobac-
terium,Bacteroides,Clostridium,andLactobacillus generaareasso-
ciatedwithinﬂammatory/autoimmunediseaseprotection.There-
fore,establishingabalancedmicrobiotainfavoroftheseprotective
commensal bacteria may be a good strategy for the preven-
tion and/or treatment of inﬂammatory/autoimmune diseases in
autoimmune-prone individuals.
INVOLVEMENT OF COMMENSAL BACTERIA IN TRIGGERING
INFLAMMATORY/AUTOIMMUNE DISEASE
Microbial pathogens have long been implicated in the etiology of
a variety of autoimmune/inﬂammatory diseases, including IBD
(Sanderson and Hermon-Taylor, 1992; Chen et al., 2000), RA
(Toivanen, 2003), experimental autoimmune encephalomyelitis
(Cermelli and Jacobson, 2000; Buljevac et al., 2005; Gilden, 2005;
Farrelletal.,2009),type1diabetes(FilippiandvonHerrath,2005),
and systemic lupus erythematosus (Cavallo and Granholm, 1990;
Zandman-GoddardandShoenfeld,2005;Pooleetal.,2006).How-
ever,a growing body of evidence suggests that speciﬁc commensal
bacteria may also negatively impact inﬂammatory and autoim-
mune diseases in genetically susceptible individuals. Interestingly,
rendering mice germ-free (GF) can dramatically alter inﬂamma-
tory/autoimmunediseaseincidenceandseverity,and/orthekinet-
ics of disease onset and progression in animal models of disease.
Thisisnotsurprisingsinceweknowthatcommensalbacteriaplay
an important role in shaping the host systemic immune response.
However, the mechanisms underlying the relationship between
commensal microorganisms and the induction/exacerbation of
autoimmune/inﬂammatory diseases are poorly understood. Fur-
thermore, it is unclear how individual microbial species compris-
ing the microbiota contribute to the effects on these diseases.
Recent studies focusing on the relationship between the micro-
biota and induction of autoimmunity have begun to shed some
light on these issues.
Most mouse models of colitis are antibiotic-responsive, and
patients with IBD often beneﬁt from treatment with antibi-
otics, suggesting that bacteria play a role in disease pathogenesis.
The general consensus is that IBD may be driven by aberrant
pro-inﬂammatory host responses to the commensal microbiota
(PackeyandSartor,2008).Arecentstudyhasfoundthatthemicro-
biota can induce inﬂammation in models of colitis by activating
T cells via both innate and adaptive immune mechanisms (Feng
etal.,2010).Inthatstudy,homeostaticproliferationof transferred
TcellswasinhibitedinGFRAG−/− mice,butrestoredafterrecon-
stitution with Altered Schaedler’s Flora (a standardized cocktail
of mouse microbiota),indicating that T cells require the presence
of the microbiota to proliferate. Moreover, microbiota-induced
production of IL-6 by DC was required to reach the threshold
number of IFNγ and IL-17-producing microbiota-speciﬁc T cells
(i.e., induction of T cell proliferation) that was needed to induce
colitis (Feng et al., 2010). In other studies, a number of bac-
terial species isolated from the intestines of IBD patients have
been shown to be capable of inducing intestinal inﬂammation in
rodents, including Helicobacter hepaticus, enterotoxigenic B. frag-
ilis, and Bacteroides vulgatus. H. hepaticus infection is associated
with the spontaneous development of colitis in some types of
immunodeﬁcient, but not immunocompetent mice (Ward et al.,
1996).Furthermore,colonizationwithenterotoxigenicstrains,but
not non-toxigenic strains,of B. fragilis have been shown to induce
colitis. Enterotoxigenic B. fragilis of human origin mediates col-
itis in multiple intestinal neoplasia (Min) transgenic mice in a
Th17 cell-dependent manner (Wu et al., 2009). Similarly, entero-
toxigenic B. fragilis of piglet origin has been shown to enhance
DSS-induced colitis in mice (Rabizadeh et al., 2007), and the B.
fragilis toxinappearstobeessentialfordiseasepathogenesis(Rhee
et al., 2009). In an older study, colitis severity was found to be
increased in a carrageenan-based model of colitis in guinea pigs
afteroraladministrationof B.vulgatus isolatedfromIBDpatients,
but not healthy individuals. This disease exacerbation could be
transferred to recipients via spleen cells (Onderdonk et al., 1984),
suggesting that bacteria isolated from IBD patients were induc-
ing a cell-mediated (most likely T cell) immune response capable
ofenhancinginﬂammation.Interestingly,anotherstudyhasfound
thatasinglespeciesofcommensalbacteria,ﬁlamentoussegmented
bacteria(SFB),caninduceintestinalinﬂammationinthepresence
of a limited microbiota (Stepankova et al., 2007). In this study,
GF SCID mice were colonized with individual or combinations
of strains of anaerobic and aerobic bacteria and SFB, including
Enterococcus faecalis, SFB, Fusobacterium mortiferum, Bacteroides
distasonis,F.mortiferum+SFB,B.distasonis +SFB,andaSPFbac-
terial cocktail with limited diversity (SPF cocktail) ±SFB. Using
the CD45high transfer model of intestinal inﬂammation,the study
found that only the mice colonized with the SPF cocktail +SFB
developedclinicalandhistologicalsignsofintestinalinﬂammation
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following transfer of CD45RBhigh cells (Stepankova et al., 2007).
These data indicate that, unlike SFB, most gut bacteria cannot or
do not trigger intestinal inﬂammation in the presence of a limited
microbiota, such as the typical SPF bacteria.
The involvement of SFB in inﬂammatory disease pathogenesis
is not limited to the intestine. Two recent studies have shown that
SFBmayalsobeinvolvedindevelopmentof experimentalautoim-
mune encephalomyelitis (EAE) (Lee et al., 2011) and rheumatoid
arthritis (RA) (Wu et al., 2010). In the ﬁrst study, the authors
foundthatGFmiceexhibiteddecreasedseverityof MOG-induced
EAE compared to mice raised under SPF conditions. The reduced
severitywasassociatedwithreducedIL-17AandIFNγproduction
andRORγttranscripts,butelevatedlevelsofCD4+CD25+Foxp3+
cells. Interestingly, whereas transfer of CD4+ T cells from MOG-
immunized GF mice into RAG−/− GF mice only induced very
mild EAE, transfer of CD4+ T cells from MOG-immunized stan-
dard pathogen free (SPF) mice induced severe disease, suggesting
that the gut microbiota plays a role in activating T cells capable
of inducing EAE. Finally, intestinal colonization of GF mice with
SFBalonerestoredsusceptibilitytosevereEAEinduction,andcor-
related with elevated IL-17 and IFNγ expression in T cells in the
spinal cord and small intestine lamina propria as well as a reduc-
tionofFoxp3+ Tcelllevels.Thisstudydemonstratesthatintestinal
colonization with SFB can induce Th17 cells that attack the cen-
tral nervous system (CNS) (Lee et al., 2011). In the second study,
arthritis-prone K/BxN mice raised under GF conditions exhib-
ited attenuated RA that was associated with a reduction in serum
autoantibodytiters,splenicautoantibody-secretingcells,germinal
centers, and IL-17. Interleukin-17 was found to be critical for the
pathogenesis of the disease in these mice, as treatment with anti-
IL-17 antibodies abrogated RA development in mice raised under
SPFconditions.Interestingly,colonizationofGFK/BxNmicewith
a single bacterial species, SFB, resulted in the rapid development
of arthritis,which correlated with restoration of IL-17-producing
T cells in the lamina propria. These cells could in turn migrate to
the spleen where they provided help for germinal center forma-
tion and antibody production (Wu et al., 2010). Therefore, SFB,
a bacterium known to induce IL-17 production (Ivanov et al.,
2009), is capable of triggering RA in arthritis-prone K/BxN mice
via activation of Th17 cells (Wu et al., 2010). Colitis, EAE, and
RA are all mediated by IL-17-producing cells, and it is perhaps
not surprising that a commensal bacteria that induces Th17 cells
may be involved in the etiology of these diseases. However, it is
surprising that a commensal gut bacteria (such as SFB) can play a
role in the development of autoimmune disease at a distant site,
i.e., CNS (Lee et al., 2011) or joints (Wu et al., 2010). In fact, evi-
dence of SFB-induced Th17 cells could be found not only in the
intestine, but also in the spinal chord and spleen, demonstrating
that a single intestinal commensal bacterial species is capable of
priming immune responses that are extra-intestinal and extend to
peripherallymphoidorgansandtissues.However,therolethatthe
intestinalSFB-inducedTh17cellsplayatthediseasesites,i.e.,inthe
spinalchordorthejoints,remainstobedetermined.Severalstud-
ies have shown that the presence of IL-17 in the joints enhanced
disease (Lubberts et al., 2004; Jacobs et al., 2009), suggesting that
Th17 cells could amplify the inﬂammatory process in the joints.
Indeed,IL-17receptorisexpressedbyawiderangeofsynovialcells
(Yao et al., 1995; Silva et al., 2003), and IL-17 drives these cells to
produce pro-inﬂammatory mediators such as cytokines (GM-
CSF)andchemokines(CXCL2,CXCL8),andinducesrecruitment
of neutrophils(Laanetal.,1999,2003).Moreover,onecouldspec-
ulate that Th17 cells may also participate in the inﬂammatory
process by producing other cytokines capable of promoting the
inﬂammatory response. For instance, IL-23 and GM-CSF have
been shown very recently to play a crucial role in EAE induc-
tion. Interleukin-23 appears to induce Th17 or RORγt+ Tc e l l st o
produce GM-CSF that is required for disease induction; this was
demonstrated in experiments showing that GM-CSF-producing
IL-17-deﬁcientTcells,butnotGM-CSF-deﬁcientTh17cells,were
able to induce EAE (Codarri et al., 2011; El-Behi et al., 2011).
Furthermore, GM-CSF seems to target the myeloid cells that are
responsibleforsustaininginﬂammationintheCNS(El-Behietal.,
2011). Depending on the type of autoimmune diseases or the
site of inﬂammation, SFB-induced Th17 cells may therefore pro-
mote/exacerbate inﬂammation in tissue through the production
of GM-CSF and/or IL-17.
Understanding the role that commensal bacteria play in dis-
ease development in humans has been challenging. Studies about
the composition of the gut microbiota in patients have identi-
ﬁed bacteria with the potential to cause disease. Nonetheless, it
is also possible that these microorganisms colonize the gut after
disease is established and are not involved in the development
of the disease. There is, however, a general consensus that IBD
arises from an abnormal immune response to bacterial com-
ponents of the intestinal microbiota (Packey and Sartor, 2008).
Indeed, it has been reported that a subset of people with Crohn’s
disease harbor a strain of adherent–invasive Escherichia coli in
their small intestine that is potentially pro-inﬂammatory (Pine-
ton de Chambrun et al., 2008). In addition, RA patients treated
with antibiotics such as minocycline exhibit signiﬁcant disease
improvement (Stone et al., 2003), suggesting that the commen-
sal bacteria contributes, at some level, to disease development.
Although it has been shown that humans can be colonized with
SFB (Klaasen et al., 1993a), there is little evidence yet for involve-
ment of SFB in inﬂammatory/autoimmune diseases in humans.
It would be of great interest to determine whether SFB is more
prominent in the microbiota of patients exhibiting certain types
of autoimmune diseases, i.e., Th17-mediated. Moreover, multiple
issues remain to be addressed concerning the involvement of SFB
in autoimmune diseases, including identifying the molecules that
mediate Th17 cell induction as well as determining whether other
Th17-mediated autoimmune diseases can be triggered by SFB.
ROLE OF THE MICROBIOTA IN ALLERGIC DISEASES
In addition to inﬂammatory and autoimmune diseases, there are
other chronic diseases that may be impacted by the gut micro-
bial community. In particular, allergic disease development has
been associated with alterations in the intestinal microbiota. The
incidence of allergic diseases has increased over the past 40years
in industrialized countries including the United States, Canada,
United Kingdom, Ireland, New Zealand, and Australia, but not
in developing countries. These data suggest that environmental
changes are a major factor in the development of allergic dis-
eases (Asher, 1998; Mannino et al., 1998; Beasley et al., 2000).
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The “hygiene hypothesis” suggests that the increase in the preva-
lence of allergic diseases observed in developed countries could
be due to decreased early exposure to infectious agents that may
alter the immune response and, in particular, the immunoregula-
tory compartment (Okada et al., 2010). However, the“microﬂora
hypothesis” has been put forth as an alternative explanation and
is based on changes in the intestinal microbiota that are due
to antibiotic use and dietary differences (Noverr and Huffnagle,
2005). In either case, the regulatory mechanisms that normally
control the Th2 responses generally associated with allergic dis-
eases and asthma would not develop properly. Indeed, treatment
of normal 3-week-old mice with the broad-spectrum antibiotic,
kanamycin, results in the elimination of all Gram-negative bacte-
ria in the stool, and a subsequent shift to a Th2 response (Oyama
et al., 2001), suggesting that intestinal bacteria are involved in
controlling the Th2 response. This was further supported in a
study showing that treatment of mice with antibiotics combined
with oral administration of the commensal fungus, Candida albi-
cans, triggers pulmonary allergic responses (Noverr et al., 2004).
Taken together, these studies suggest that the microbiota plays an
important role in controlling allergic diseases.
Several studies have reported differences in the composition of
the microbiota of infants who develop allergic diseases. Infants
with food allergies were found to exhibit an imbalance between
“beneﬁcial”and potentially harmful bacteria, i.e., Lactobacilli and
Biﬁdobacteria specieswerelowerwhilecoliformsand Staphylococ-
cus aureus were higher (Bjorksten et al., 1999). Decreased levels
of Biﬁdobacteria were also observed in infants with atopic eczema
(Kirjavainen et al., 2001). Moreover, Biﬁdobacteria and Entero-
coccus were decreased while Clostridium was increased, resulting
i nar e d u c e dr a t i oo fBiﬁdobacteria to Clostridia in infants that
developed atopic dermatitis (Bjorksten et al., 2001). These data
suggest that speciﬁc species of intestinal commensal bacteria can
play either a pathogenic or protective role in allergies that occur
in the gut or at sites distant from the gut, such as lung and skin.
Prophylacticapproachesbasedontheadministrationof probi-
otics to newborns at high risk for allergies have proven successful.
The World Health Organization has deﬁned probiotics as “live
microorganisms which when administered in adequate amounts
confer a health beneﬁt on the host” FAO/WHO (2002). Admin-
istration of L. casei GG to the mothers before and after (via
breastfeeding) delivery prevents atopic eczema, as well as other
atopic diseases that develop later, in children at risk (Kalliomaki
et al., 2001, 2003). Protection from allergic diseases provided by
oral administration of non-pathogenic E. coli in early life was
shown to extend to adult life (Lodinova-Zadnikova et al., 2003).
Finally,anumberof studieshavebeenperformedusingprobiotics
to treat pre-existing atopic disease in infants. These studies found
thatadministrationof Lactobacilli wasabletodecreasetheseverity
of various allergic diseases, including atopic eczema, atopic der-
matitis,and food allergy in these children (Majamaa and Isolauri,
1997; Kirjavainen et al., 1999; Rosenfeldt et al., 2003; Viljanen
et al.,2005). There is no evidence to date indicating that probiotic
therapies have a beneﬁcial effect on the incidence or severity of
asthma in children at high risk (Vliagoftis et al., 2008). However,
studies using animal models have found that oral administration
of certain Lactobacilli and Biﬁdobacterium species were able to
modulate allergic responses in the respiratory tract apparently via
inductionofregulatoryTcells,suggestingthatitmaybepossibleto
treatasthmausinganoptimalcombinationofprobiotics(Feleszko
et al., 2007; Forsythe et al., 2007; Karimi et al., 2009; Lyons et al.,
2010).
As described above for autoimmune diseases, microbiota that
favorcertainspeciesof commensalbacteriaappearstoalsopredis-
pose or protect susceptible individuals to allergy development at
variousextra-intestinalsites,includinglungandskin.Themecha-
nisms by which intestinal immune responses affect inﬂammatory
responses at distant sites are still unknown and remain to be
established.
ROLE OF THE MICROBIOTA IN CANCER
The intestinal microbiota does not only inﬂuence autoimmune
and allergic diseases, but has also been implicated in the devel-
opment of cancer, especially colon cancer. Colorectal cancer is
highly prevalent in the United States, with an estimated 1 in
20 men and women receiving a diagnosis of colon or rectum
cancer sometime during their lifetime (National Cancer Insti-
tute Website: http://seer.cancer.gov/statfacts/html/colorect.html).
Similarly,colorectal cancer is the second and third most common
cancerinwomenandmen,respectively,inEuropeanUnioncoun-
tries (Ferlay et al., 2007). This is an important heath problem in
developed countries,where the primary risk factor is diet in up to
80% of all colorectal cancers (Bingham, 2000).
Interestingly, accumulating evidence in the last 3years has
underscored the importance of the intestinal microbiota in the
development of colorectal cancer (Bingham,2000;Davis and Mil-
ner, 2009; O’Keefe et al., 2009; Uronis et al., 2009). In fact, diet
and the composition of the microbiota strongly correlate with the
risk of developing colorectal cancer in certain groups of individu-
als (Bingham,2000; Davis and Milner,2009; O’Keefe et al.,2009).
One mechanism by which commensal bacteria contribute to the
initiation of colorectal cancer involves the induction of inﬂam-
mation by commensal bacteria. A study using an animal model
of colorectal carcinoma, IL-10−/− mice exposed to the carcino-
gen, azoxymethane (AOM) tested this hypothesis. In this study,
AOM-exposed IL-10−/− mice developed colorectal carcinomas
whenhousedconventionally,butnotwhenhousedunderGFcon-
ditions. Furthermore,MyD88 (an adaptor molecule necessary for
mostTLRsignaling)wasfoundtobeessentialinthisprocess,sug-
gesting that bacterial-induced inﬂammation in the intestine can
play a crucial role in the development of the carcinomas (Uro-
nis et al., 2009). Interestingly, ingestion of lactic acid-producing
bacteria has been shown to prevent carcinogen-induced lesions
and tumors in animal models (Goldin and Gorbach,1980;Goldin
et al., 1996; Pool-Zobel et al., 1996; Challa et al., 1997; Rowland
et al.,1998). However,the epidemiologic studies are controversial
in humans; some studies have found no association (Kampman
et al., 1994a,b; Kearney et al., 1996), whereas others have found a
signiﬁcantassociation(Malhotra,1977;Petersetal.,1992;Boutron
etal.,1996)betweenconsumptionoffermentedmilkproductsand
occurrence of colon cancer. Further studies are, therefore, needed
to determine if probiotics can be used as protective agents for the
prevention of human colon cancer.
Unlike the situation in autoimmune and allergic diseases,
there is little evidence that the microbiota directly affects the
immune response against tumors, and consequently, somehow
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impacts tumor progression. One can, however, speculate that
the type of immune response generated by the gut commen-
sal bacteria could potentially inﬂuence tumor immunity. For
example, mice colonized with enterotoxigenic B. fragilis exhibit
colonic Th17 inﬂammatory inﬁltrates that are involved in induc-
tion of colon tumors, as indicated by inhibition of colon tumor
formation following treatment with anti-IL-17 antibody (Wu
et al., 2009). Moreover, Th17 cells have been found in cellular
inﬁltrations in a variety of tumors, including prostate (Sfanos
et al., 2008), pancreatic (Gnerlich et al., 2010), and ovarian
cancer (Kryczek et al., 2009a), and in stomach cancer and the
lymph nodes draining gastric cancer sites (Zhang et al., 2008).
The frequency of Th17 cells correlates with the clinical stage
of gastric cancer, i.e., Th17 cells are found at higher levels in
late stage versus early stage (Zhang et al., 2008). On the other
hand, Th17 cells appear to have a beneﬁcial role in human
ovarian cancer (Kryczek et al., 2009a) and murine melanoma,
pancreatic, and colon cancer (Muranski et al., 2008; Kryczek
et al., 2009b; Gnerlich et al., 2010). It is, therefore, possible
that a microbiota favoring commensal bacteria that induces a
Th17 response could have differential effects on tumors depend-
ing on the type of tumor or the stage of tumor develop-
ment, and as found for autoimmunity and allergy, could alter
the immune response to tumors at extra-intestinal as well as
intestinal sites.
CONCLUSION
Genetic and environmental factors appear to shape the compo-
sition of the gut microbiota, which in turn plays a very impor-
tant role in shaping the immune response at both intestinal and
extra-intestinal sites, and in controlling the development of some
types of autoimmune and allergic diseases as well as some forms
of cancer. Therefore, any external factor that can alter the gut
microbiotabalance,suchasdietorantibiotictreatment,shouldbe
viewed as a potential risk factor for development of these inﬂam-
matory diseases. Any alteration of the microbiota that leads to
(1) a reduction in commensal bacteria favoring regulatory cells
(Foxp3+ or other, e.g., rTh17) or (2) an enrichment in commen-
sal bacteria favoring the induction of potential pathogenic cells
may elicit disease in genetically susceptible individuals (Figure1).
However,therelationshipbetweengutmicrobiota,immunity,and
disease is very complex, since the same commensal bacteria can
induce a protective response or a pathogenic response depending
on the susceptibility of the individual. SFB is the perfect exam-
ple, since it is protective in type 1 diabetes, but causes disease
in mouse models of EAE or arthritis. The speciﬁc commensal
microorganisms that contribute to either the etiology of or pro-
tection from many different types of diseases have not yet been
fully identiﬁed and described. Future studies aimed at determin-
ing the impact of speciﬁc commensal bacteria on the immune
response and induction of inﬂammatory diseases are crucial for
a better understanding of pathogenesis of these diseases. Further-
more, an understanding of the genetic and environmental factors
thatshapethecompositionofthemicrobiotawillprovidethebasis
for strategies that will allow for the manipulation of microbiota in
individuals at risk of developing disease. With this information in
hand,itshouldbepossibletodesignnoveltailoredtherapiescapa-
bleof preventingdiseasedevelopmentinhighriskindividualsand
treating established disease in already sick patients. Although not
discussed in this review, other microorganisms, such as fungi and
FIGURE 1 | Impact of the composition of the ﬂora on the immune
response and disease development. Dysbiosis can arise from either (1) a
reduction inTreg-inducing bacteria (e.g., Biﬁdobacteria or Bacteroides) that
results in decreasedTregs, but unchanged levels ofTeff cells; or (2) an
enrichment in pro-inﬂammatory bacteria (e.g., SFB) that results in increased
Teff cells, but unchanged levels ofTregs. In both cases, theTreg:Teff cell
balance is biased toward theTeff cells, and the outcome of this imbalance can
be development of disease in genetically susceptible individuals.
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viruses,arepresentintheintestine,andhavealsobeenshowntobe
involvedinautoimmunediseaseorallergicdiseasepathogenesisin
susceptible animals (Noverr et al., 2004; Cadwell et al., 2010). It
would, therefore, be very important in the future to extend the
studies cited above to these microorganisms rather than limiting
them to commensal bacteria only. It may eventually be possible
to establish proﬁles of the microbiota in humans based on the
bacterial species composition or enterotypes (Arumugam et al.,
2011). This“biological ﬁngerprint”of the future,similar to blood
or tissue typing,may be used to predict responses to drugs or diet
as well as aid in disease diagnosis/prognosis, and could ultimately
lead to the development of personalized therapies.
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